/stocks — the workspaceLOADING
Senti Biosciences Holdings, Inc. (SNTI) is a biological products, (no diagnostic substances) company. Piotroski F-Score 2/7. Next earnings projected around 2026-11-12 from SNTI's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
What’s behind SNTI’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
FY ending 2025-12-31 vs 2024-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from SNTI’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on SNTI plus an auto-SWOT — built from SNTI's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate SNTI using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Has SNTI been issuing shares? Offering history →
The fair-value line is SNTI’s own median P/E, P/S, P/B and P/FCF applied to each year’s fundamentals — the price its typical valuation would have implied. Where the solid line sits above the dashed one, the stock traded at a premium to its own history that year; below, a discount. This is a description of past valuation, computed from SNTI’s filings and price history — not a forecast and not investment advice. A stock can trade above or below its own median for years.
Total return including reinvested dividends, from SNTI’s adjusted closing prices. Past return is not a forecast and not investment advice.
Projected from SNTI's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentSNTI files or announces.
SNTI has sold off after 5 of its last 8 earnings reports.
Each figure is one earnings reaction — how much SNTI moved from the closing price the day before a report to the close the day after. Based on its last 8 reports.
Large earnings reactions have been common.
SNTI has traded lower after most recent earnings releases.
The average is inflated by its most volatile prints (+4.9% and -52.5%).
A more typical earnings reaction has been approximately ±5.7%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-07-15 | -52.5% |
| 2026-05-14 | +4.9% |
| 2026-03-27 | -12.4% |
| 2025-11-13 | -14.8% |
| 2025-08-07 | -6.5% |
| 2025-05-06 | +1.2% |
| 2025-03-20 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| +1.7% |
| 2024-11-14 | -4.4% |